Key result
Direct oral factor Xa inhibitors lowered the risk of VTE recurrence compared to dalteparin but increased major bleeding.
Why the study?
The study was conducted to explore the efficacy and safety of direct oral factor Xa inhibitors compared with dalteparin, and to compare apixaban, rivaroxaban, and edoxaban in cancer-associated acute VTE.
Do direct oral factor Xa inhibitors reduce VTE recurrence compared to dalteparin in patients with cancer-associated acute VTE?
Meta-Analysis (n=1,739)
Do direct oral factor Xa inhibitors reduce VTE recurrence compared to dalteparin in patients with cancer-associated acute VTE?
Answers are grounded in this paper and cite their sources.
In patients with cancer-associated acute VTE, direct oral factor Xa inhibitors reduce VTE recurrence but increase major bleeding compared to dalteparin, with apixaban potentially offering the greatest reduction in recurrence.
e23156 Background: A direct meta-analysis was performed to explore the efficacy and safety of direct oral factor Xa inhibitors with dalteparin in patients with cancer associated acute venous thromboembolism (VTE). Also, the comparative efficacy and safety of apixaban, rivaroxaban, and edoxaban was assessed with a network meta-analysis. Methods: MEDLINE, CENTRAL, and EMBASE were searched for trials comparing direct oral anticoagulants (DOACs) to dalteparin for the management of cancer associated acute VTE. A network meta-analysis using both frequentist and Bayesian methods was performed to analyze VTE recurrence, major and clinically relevant non-major bleeding (CRNMB). Results: Three randomized control trials, at low risk of bias, enrolled 1,739 patients with cancer associated VTE. Direct comparison showed a lower rate of VTE recurrence in DOAC compared to dalteparin groups (odds Ratio [OR]:0.48, 95% Confidence interval [CI]:0.24-0.96; I2:46%). Indirect comparison suggested that apixaban had greater reduction in VTE recurrence compared to dalteparin (OR: 0.10; 95% CI: 0.01–0.82), but not rivaroxaban or edoxaban. Apixaban also had the highest probability of being ranked most effective. By direct comparisons, there was an increased likelihood of major bleeding in the DOAC group compared to dalteparin (OR: 1.70; 95% CI: 1.04–2.78). CRNMB did not differ. Indirect estimates were imprecise. Subgroup analyses in gastrointestinal cancers suggested that dalteparin may have the lowest risk of bleeding whereas estimates in urothelial cancer were imprecise. Conclusions: DOACs appear to lower the risk of VTE recurrence compared to daltaparin while increasing major bleeding. Apixaban may be associated with the lowest risk of VTE recurrence compared to the other DOACs.
No takes yet. Share an insight, caveat, or question.
Fuentes et al. (2019) conducted a meta-analysis in cancer associated acute venous thromboembolism (VTE) (n=1,739). Direct oral factor Xa inhibitors (DOACs) vs. dalteparin was evaluated on VTE recurrence (OR 0.48, 95% CI 0.24-0.96). Direct oral factor Xa inhibitors lowered the risk of VTE recurrence compared to dalteparin but increased major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: